Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 73
Selected: 0
NCT IDTitle
NCT01027598Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
NCT01038856Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
NCT00085826A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
NCT01334710A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
NCT008410357 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
NCT00733746Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT00294762Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
NCT00036257Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
NCT01557959Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00046800Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
NCT00042055CP-461 for the Treatment of Crohn's Disease
NCT00283803Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
NCT00036036Study of CP-461 in Patients With Advanced Renal Cell Cancer
NCT01003938Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
NCT00304278Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
NCT00036075Study Using CP-461 to Treat Advanced Prostate Cancer
NCT00940316Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
NCT00369512A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
NCT00254410FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
NCT00116909A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy
NCT01515137Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT00497224Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
NCT01032070Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
NCT00871923Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
NCT00385996Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
NCT00609804Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
NCT00036647OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00826449Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
NCT00166426Exisulind Versus Placebo After Surgical Removal of the Prostate
NCT00739063Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
NCT00033241Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
NCT00073502Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
NCT00942734Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
NCT00088270A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer
NCT00072631Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT01427205Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT00696696Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
NCT00116896Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
NCT00532441Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
NCT01154335Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
NCT01299220Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)
NCT00950365Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
NCT00603356Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
NCT00642746Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
NCT00373425A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
NCT00139620A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
NCT01180959Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
NCT01006096Erlotinib for Treatment of Psoriasis
NCT00060710CP-461 in the Treatment of Patients With Advanced Melanoma
NCT01247922Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205